Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder After Bacillus Calmette-Guerin Failure
Sponsor: Cell Genesys
Listed as NCT00109655, this PHASE1 trial focuses on Bladder Neoplasms and Carcinoma, Transitional Cell and remains ongoing. Sponsored by Cell Genesys, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1
First recorded
Apr 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cell Genesys
For direct contact, visit the study record on ClinicalTrials.gov .